Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

Oncogene

Volumn 28, Issue 6, 2009, Pages 803-814

  Scaltriti, M ^a   Verma, C ^b   Guzman, M ^a   Jimenez, J ^c   Parra, J L ^a   Pedersen, K ^a   Smith, D J ^b   Landolfi, S ^c   Ramon Y Cajal, S ^c   Arribas, J ^a   Baselga, J ^a,c,d  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b BIOINFORMATICS INSTITUTE   (Singapore)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Antibody dependent cell cytotoxicity (ADCC); Breast cancer; ErbB receptor; Trastuzumab; Tyrosine kinase inhibitor

Indexed keywords

DIMER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; LAPATINIB; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL SURFACE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE SYSTEM; IMMUNOPRECIPITATION; IN VIVO STUDY; MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR REGRESSION; UBIQUITINATION;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MEMBRANE; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEOPLASM TRANSPLANTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, ERBB-2; REMISSION INDUCTION; SIGNAL TRANSDUCTION;

EID: 60149109196     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.432     Document Type: Article

References (62)

1. Anido J, Matar P, Albanell J, Guzman M, Rojo F, Arribas J et al. (2003). ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 9: 1274-1283.
2. Arteaga CL, Ramsey TT, Shawver LK, Guyer CA. (1997). Unliganded epidermal growth factor receptor dimerization induced bydirect interaction of quinazolines with the ATP binding site. J Biol Chem 272: 23247-23254.
3. Austin CD, De Maziere AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX et al. (2004). Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 15: 5268-5282.
4. Baselga J. (2006). Targeting tyrosine kinases in cancer: the second wave. Science 312: 1175-1178.
5. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. (1998). Recombinant humanized anti-HER2 antibody(Herceptin ) enhances the antitumor activityof paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825-2831.
6. Baselga J, Schoffski F, Rojo F, Dumez H, Ramos FL, Macarulla T et al. (2006). A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody(MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and nonsmall cell lung cancer (NSCLC). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 3006.
7. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L et al. (1996). Phase II studyof weeklyintravenous recombinant humanized anti-p185HER2 monoclonal antibodyin patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14: 737-744.
8. Bleeker WK, Lammerts van Bueren JJ, van Ojik HH, Gerritsen AF, Pluyter M, Houtkamp M et al. (2004). Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol 173: 4699-4707.
9. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M. (1983). CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J Comp Chem 4: 187-217.
10. Citri A, Yarden Y. (2006). EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7: 505-516.
11. Clynes RA, Towers TL, Presta LG, Ravetch JV. (2000). Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6: 443-446.
12. Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM et al. (2001). Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 61: 4892-4900.
13. Chu I, Blackwell K, Chen S, Slingerland J. (2005). The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 65: 18-25.
14. Diermeier S, Horvath G, Knuechel-Clarke R, Hofstaedter F, Szollosi J, Brockhoff G. (2005). Epidermal growth factor receptor coexpression modulates susceptibilityto Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res 304: 604-619.
15. Gan HK, Walker F, Burgess AW, Rigopoulos A, Scott AM, Johns TG. (2007). The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapywith monoclonal antibody806. J Biol Chem 282: 2840-2850.
16. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E et al. (2004). Pilot studyof the mechanism of action of preoperative trastuzumab in patients with primaryoperable breast tumors overexpressing HER2. Clin Cancer Res 10: 5650-5655.
17. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T et al. (2006). Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733-2743.
18. Henson ES, Hu X, Gibson SB. (2006). Herceptin sensitizes ErbB2-overexpressing cells to apoptosis byreducin g antiapoptotic Mcl-1 expression. Clin Cancer Res 12: 845-853.
19. Hommelgaard AM, Lerdrup M, van Deurs B. (2004). Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. Mol Biol Cell 15: 1557-1567.
20. Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM. (2004). Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 64: 5355-5362.
21. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. (2002). Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416: 279-280.
22. Johns TG, Luwor RB, Murone C, Walker F, Weinstock J, Vitali AA et al. (2003). Antitumor efficacyof cytotoxic drugs and the monoclonal antibody806 is enhanced by the EGF receptor inhibitor AG1478. Proc Natl Acad Sci USA 100: 15871-15876.
23. Kim JY, Sun Q, Oglesbee M, Yoon SO. (2003). The role of ErbB2 signaling in the onset of terminal differentiation of oligodendrocytes in vivo. J Neurosci 23: 5561-5571.
24. Klapper LN, Waterman H, Sela M, Yarden Y. (2000). Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res 60: 3384-3388.
25. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M et al. (2006). Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66: 1630-1639.
26. Li X, Shen L, Zhang J, Su J, Liu X, Han H et al. (2007). Degradation of HER2 by Cbl-based chimeric ubiquitin ligases. Cancer Res 67: 8716-8724.
27. Lichtner RB, Menrad A, Sommer A, Klar U, Schneider MR. (2001). Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res 61: 5790-5795.
28. Longva KE, Pedersen NM, Haslekas C, Stang E, Madshus IH. (2005). Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int J Cancer 116: 359-367.
29. Lu Y, Li X, Liang K, Luwor R, Siddik ZH, Mills GB et al. (2007). Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res 67: 8240-8247.
30. Marmor MD, Yarden Y. (2004). Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene 23: 2057-2070.
31. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M et al. (2005). Randomized phase II trial of the efficacy and safetyof trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23: 4265-4274.
32. Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J et al. (2004). Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 10: 6487-6501.
33. Milella M, Trisciuoglio D, Bruno T, Ciuffreda L, Mottolese M, Cianciulli A et al. (2004). Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene - amplified breast cancer cells. Clin Cancer Res 10: 7747-7756.
34. Mimura K, Kono K, Hanawa M, Kanzaki M, Nakao A, Ooi A et al. (2005). Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res 11: 4898-4904.
35. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G et al. (2008). Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapyin patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26: 1789-1796.
36. O'Shaughnessy J, Blackwell KL, Burstein H, Storniolo AM, Sledge G, Baselga J et al. (2008). A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 26(Suppl): abstract 1015.
37. Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, Hubner N et al. (2002). Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci USA 99: 8880-8885.
38. Perera RM, Narita Y, Furnari FB, Gan HK, Murone C, Ahlkvist M et al. (2005). Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res 11: 6390-6399.
39. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659-1672.
40. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer Jr CE, Davidson NE et al. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684.
41. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N et al. (2001). The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1: 85-94.
42. Sali A, Blundell TL. (1993). Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234: 779-815.
43. Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J et al. (2007). Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99: 628-638.
44. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM et al. (2007). Escape from HER-familyty rosine kinase inhibitor therapy bythe kinase-inactive HER3. Nature 445: 437-441.
45. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M et al. (2008). NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68: 8022-8030.
46. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Pawlicki M et al. (2005). Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive earlybreast cancer patients: BCIRG 006 study. 28th Annual San Antonio Breast Cancer Symposium abstract 1. San Antonio, TX, USA (abstract 1).
47. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182.
48. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712.
49. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. (2001). Use of chemotherapyplus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792.
50. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. (1999). Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26: 60-70.
51. Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM. (2007). Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol 179: 2815-2823.
52. Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW et al. (2006). Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells byusin g a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Mol Pharmacol 70: 1534-1541.
53. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S et al. (1996). A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16: 5276-5287.
54. Valabrega G, Montemurro F, Sarotto I, Petrelli A, Rubini P, Tacchetti C et al. (2005). TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. Oncogene 24: 3002-3010.
55. Wang Z, Zhang L, Yeung TK, Chen X. (1999). Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation. Mol Biol Cell 10: 1621-1636.
56. Wolpoe ME, Lutz ER, Ercolini AM, Murata S, Ivie SE, Garrett ES et al. (2003). HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. J Immunol 171: 2161-2169.
57. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH et al. (2004). A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64: 6652-6659.
58. Xia W, Gerard CM, Liu L, Baudson NM, Ory TL, Spector NL. (2005). Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 24: 6213-6221.
59. Yarden Y, Sliwkowski MX. (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137.
60. Yuste L, Montero JC, Esparis-Ogando A, Pandiella A. (2005). Activation of ErbB2 by overexpress ion or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin. Cancer Res 65: 6801-6810.
61. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. (2006). An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125: 1137-1149.
62. Zheng JH, Trafny EA, Knighton DR, Xuong NH, Taylor SS, Ten Eyck LF et al. (1993). 2.2-angstrom refined crystal-structure of the catalytic subunit of cAMP-dependent protein-kinase complexed with MnATP and a peptide inhibitor. Acta Crys D 49: 362-365.